Header Logo

Connection

Jonathan Kay to Adult

Back to Details
This is a "connection" page, showing publications Jonathan Kay has written about Adult.
Jonathan Kay
Connection Strength
0.699
Adult
  1. Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022 09; 8(2).
    View in: PubMed
    Score: 0.063
  2. Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic equivalence of CT-P17 to high-concentration (100?mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clin Transl Sci. 2021 07; 14(4):1280-1291.
    View in: PubMed
    Score: 0.057
  3. Liu SH, Morais SA, Lapane KL, Kay J. Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. Semin Arthritis Rheum. 2020 04; 50(2):289-302.
    View in: PubMed
    Score: 0.052
  4. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22.
    View in: PubMed
    Score: 0.040
  5. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40.
    View in: PubMed
    Score: 0.035
  6. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46.
    View in: PubMed
    Score: 0.034
  7. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan; 73(1):62-8.
    View in: PubMed
    Score: 0.034
  8. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40.
    View in: PubMed
    Score: 0.026
  9. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, Colvin RB, Duncan LM, Mandal RV, Kay J. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med. 2009 Dec; 133(12):1943-8.
    View in: PubMed
    Score: 0.026
  10. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9.
    View in: PubMed
    Score: 0.026
  11. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41.
    View in: PubMed
    Score: 0.022
  12. Shridharmurthy D, Lapane KL, Baek J, Nunes AP, Weisman MH, Kay J, Liu SH. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024 08; 76(8):1149-1161.
    View in: PubMed
    Score: 0.018
  13. Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
    View in: PubMed
    Score: 0.016
  14. Lapane KL, Dub? C, Ferrucci K, Khan S, Kuhn KA, Yi E, Kay J, Liu SH. Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. BMC Fam Pract. 2021 12 20; 22(1):251.
    View in: PubMed
    Score: 0.015
  15. Lapane KL, Shridharmurthy D, Khan S, Lindstrom D, Beccia A, Yi E, Kay J, Dube C, Liu SH. Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. PLoS One. 2021; 16(5):e0252018.
    View in: PubMed
    Score: 0.014
  16. Shridharmurthy D, Zhao D, Lapane KL, Baek J, Kay J, Liu SH. Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. J Womens Health (Larchmt). 2021 11; 30(11):1637-1644.
    View in: PubMed
    Score: 0.014
  17. Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
    View in: PubMed
    Score: 0.013
  18. Kay JH, Altshuler LL, Ventura J, Mintz J. Prevalence of axis II comorbidity in bipolar patients with and without alcohol use disorders. Ann Clin Psychiatry. 1999 Dec; 11(4):187-95.
    View in: PubMed
    Score: 0.013
  19. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew? R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111.
    View in: PubMed
    Score: 0.013
  20. Baecklund E, Backlin C, R?nnelid J, Toes R, Huizinga T, ?hlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 07; 47(4):270-275.
    View in: PubMed
    Score: 0.011
  21. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul; 76(7):1279-1284.
    View in: PubMed
    Score: 0.011
  22. Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol. 1996 Aug; 7(8):1235-40.
    View in: PubMed
    Score: 0.010
  23. Duryea J, Russell R, Gravallese EM, Kay J, Han R, Lu B, Solomon DH. Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. Arthritis Rheumatol. 2016 Feb; 68(2):332-6.
    View in: PubMed
    Score: 0.010
  24. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun; 75(6):1081-91.
    View in: PubMed
    Score: 0.010
  25. Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016 Nov; 19(11):1143-1156.
    View in: PubMed
    Score: 0.010
  26. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun; 74(6):1051-7.
    View in: PubMed
    Score: 0.009
  27. Kay J, Czop JK. Enhancement of human monocyte beta-glucan receptors by glucocorticoids. Immunology. 1994 Jan; 81(1):96-102.
    View in: PubMed
    Score: 0.009
  28. Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
    View in: PubMed
    Score: 0.008
  29. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55.
    View in: PubMed
    Score: 0.008
  30. Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
    View in: PubMed
    Score: 0.008
  31. Kay J, Preibisz JM. Lyme disease. Compr Ther. 1993; 19(4):157-62.
    View in: PubMed
    Score: 0.008
  32. Schneeberger D, Tyndall A, Kay J, S?ndergaard KH, Carreira PE, Morgiel E, Deuschle K, Derk CT, Widuchowska M, Walker UA. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013 Mar; 52(3):560-7.
    View in: PubMed
    Score: 0.008
  33. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum. 1992 Aug; 35(8):926-32.
    View in: PubMed
    Score: 0.008
  34. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
    View in: PubMed
    Score: 0.007
  35. Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7.
    View in: PubMed
    Score: 0.007
  36. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, Felson D, Hawker G, Hazes JM, Huizinga T, Kay J, Kvien TK, Smolen JS, Symmons D, Tak PP, Silman A. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010 Sep; 69(9):1589-95.
    View in: PubMed
    Score: 0.007
  37. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009 Jul; 36(7):1371-9.
    View in: PubMed
    Score: 0.006
  38. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med. 2006 Dec 21; 355(25):2678-89.
    View in: PubMed
    Score: 0.005
  39. Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J. 1983 Aug; 76(8):1008-10.
    View in: PubMed
    Score: 0.004
  40. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol. 1998 Jun; 22(6):729-35.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.